Epic Sciences to present at World CDx Boston 2015.
Epic Sciences, Inc. (“Epic Sciences”), announced today that Murali Prahalad, Ph.D., president and CEO, is scheduled to present at the World CDx Boston 2015, taking place at the Hilton Boston Logan Airport, September 8 – 11, 2015.
Dr. Prahalad will give a presentation entitled, “Matching The Spectrum of Cellular Heterogeneity to the Spectrum of Therapeutic Response in Cancer.”
The details of the presentation are as follows:
- Date: Thursday, September 10, 2015
- Track: Targeted Therapies and Bio-Fluid Diagnostics
- Time: 11:45 a.m. ET
Over the past several years, there has been a growing appreciation of cancer’s heterogeneity — the genomic and cellular diversity that exists within each patient’s cancer. Individual populations of these rare cells can develop resistance to therapies and continue to grow and evolve, resulting in metastatic cancers that are unresponsive to many standard of care treatments. At World CDx, Dr. Prahalad will discuss how Epic Sciences’ “no cell left behind” technology can identify and characterize all sub-types of circulating tumor cells (CTCs) in the blood, a technical advantage enabling real-time insight into cancer heterogeneity that is necessary to improve drug development and optimize the clinical trials of targeted or combination therapies.
“In essence, cancer is not a disease of averages but a disease of multiple cell populations, each with its own unique genomic profile, that occur simultaneously in patients,” said Murali Prahalad, Ph.D., President and CEO of Epic Sciences. “Because Epic Sciences’ “no cell left behind” technology enables real-time detection of proteomic and genomic aberrations at the single cell level, we can identify those clones driving therapy resistance and provide a better understanding of drug response to optimize companion diagnostic development.”
World CDx Boston 2015 will bring together drug, diagnostic, and technology developers from target identification to launch of drug-CDx combinations to share latest clinical trial results and technological advancements, with the goal to accelerate personalized healthcare products to market. In recognition of the growing importance of liquid biopsy in cancer diagnostics, this year’s agenda includes a liquid biopsy stream for the first time.
About Epic Sciences
At Epic Sciences, we develop clinically proven predictive tests to detect and monitor cancer at the individual cell level. With a proprietary rare-cell detection engine, we provide insights to clinical, biotech, pharmaceutical and academic teams on how cancer emerges, mutates and remits so they can make pivotal decisions at every point in patient treatment with greater certainty. Recognizing the unique nature of each person’s cancer, we offer truly personalized diagnostic tests, while being non-invasive for the patient.
We have developed the first clinically proven predictive test for metastatic castration-resistant prostrate cancer (mCRPC), the Epic AR-V7 test. Using the same rare-cell detection platform and Epic’s biobank of over 30,000 blood samples, each profiled with predictive biomarkers, we partner with leading pharmaceutical and biotechnology companies, major cancer centers, the National Cancer Institute (NCI), and the National Institutes of Health (NIH) to pursue additional predictive tests for breast, ovarian, colon and other cancers and diseases. Our mission is to revolutionize cancer care and therapies to make them as precise, safe and life-sustaining as humanly possible.
For more information, visit epicsciences.com.
Stay in touch on LinkedIn, on Twitter@EpicSciences and Facebook.com/EpicSciences.
Epic Sciences Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com,+1.858.344.8091